Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
企業コードBBLGW
会社名Bone Biologics Corp
上場日Nov 27, 2015
最高経営責任者「CEO」Mr. Jeffrey Frelick
従業員数- -
証券種類Company Warrant
決算期末- -
本社所在地2 Burlington Woods Dr Ste 100
都市BURLINGTON
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号01803-4551
電話番号17815524452
ウェブサイトhttps://www.bonebiologics.com/
企業コードBBLGW
上場日Nov 27, 2015
最高経営責任者「CEO」Mr. Jeffrey Frelick
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし